08:35 AM EDT, 07/17/2024 (MT Newswires) -- Crescita Therapeutics ( CRRTF ) , a company in the commercial dermatology market, on Wednesday said it has signed a distribution agreement with NanoPass Technologies, which develops and commercialises advanced intradermal delivery devices, to launch and distribute MicronJet 600 in the Canadian medical aesthetics market.

MicronJet is an intradermal injection device that offers an effective, consistent and virtually pain-free delivery of aesthetic products and therapeutic substances. It can be attached to standard syringes and allows administration to the full face and sensitive areas such as around the eyes and neck.

Crescita will be responsible for obtaining regulatory approval for MicronJet from Health Canada. The product is expected to be launched in the first half of next year.